Trademark Overview
On Wednesday, January 29, 2025, a trademark application was filed for XOFLX with the United States Patent and Trademark Office. The USPTO has given the XOFLX trademark a serial number of 79417533. The federal status of this trademark filing is NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER as of Thursday, February 20, 2025. This trademark is owned by Oxford Genetics Ltd. The XOFLX trademark is filed in the Chemical Products, Pharmaceutical Products, and Computer & Software Services & Scientific Services categories with the following description:
Chemical and biological reagents for medical and veterinary use; diagnostic and test reagents for medical and veterinary use; human and animal cells and parts thereof for medical and veterinary purposes; microorganisms for medical and veterinary purposes; viral vectors for medical and veterinary purposes; lentiviruses, lentivirus particles and lentivirus plasmids, all for medical and veterinary use.
Chemical and biological substances for use in science and industry; nucleic acids; nucleic recombinant acids, synthetic deoxyribonucleic acids; chemical and biological reagents for non-medical purposes; chemical and biological reagents for scientific and research purposes; human and animal cells and parts thereof for non-medical purposes; microorganisms for non-medical purposes; human and animal cells and parts thereof for scientific and research purposes; microorganisms for scientific and research purposes; viral vectors for use in science and industry; lentiviruses, lentivirus particles and lentivirus plasmids, all for scientific and research purposes.
Design services relating to the creation and alteration of chemical and biological reagents; design services relating to the creation and alteration of nucleic recombinant acids and synthetic deoxyribonucleic acids; design services relating to the creation and alteration of recombinant viruses; design services relating to the creation and alteration of lentiviruses, lentivirus particles and lentivirus plasmids; research, development and bioengineering services relating to lentiviruses; drug discovery services; design services relating to the creation and alteration of cell lines, elementary cells and parts thereof; design services relating to the creation and alteration of viral vectors; information and advice relating to all the aforesaid services.
